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A B S T R A C T
This work describes the formulation and evaluation of dissolving microneedle patches (MNs) for intradermal
delivery of heat-inactivated bacteria. Pseudomonas aeruginosa, strain PA01, was used as a model bacterium.
Utilising a simple, cost eﬀective fabrication process, P. aeruginosa was heat-inactivated and formulated into
dissolving MNs, fabricated from aqueous blends of 20% w/w poly(methylvinylether/maleic acid). The resultant
MNs were of suﬃcient mechanical strength to consistently penetrate a validated skin model Paraﬁlm M®, in-
serting to a depth of between 254 and 381 µm. MNs were successfully inserted into murine skin and partially
dissolved. Analysis of MN dissolution kinetics in murine ears via optical coherence tomography showed almost
complete MN dissolution 5min post-insertion. Mice were vaccinated using these optimised MNs by application
of one MN to the dorsal surface of each ear (5 min). Mice were subsequently challenged intranasally (24 h) with a
live culture of P. aeruginosa (2×106 colony forming units). Bacterial load in the lungs of mice vaccinated with P.
aeruginosaMNs was signiﬁcantly (p= 0.0059) lower than those of their unvaccinated counterparts. This proof of
concept work demonstrates the potential of dissolving MNs for intradermal vaccination with heat-inactivated
bacteria. MNs may be a cost eﬀective, potentially viable delivery system, which could easily be implemented in
developing countries, allowing a rapid and simpliﬁed approach to vaccinating against a speciﬁc pathogen.
1. Introduction
Vaccination is undoubtedly one of the greatest breakthroughs of
modern medicine. Despite this, there remain signiﬁcant challenges
surrounding vaccine distribution, delivery and eﬃcacy, particularly
within developing countries (Oyston and Robinson, 2012). Most vac-
cines are administered via a hypodermic needle, necessitating trained
personnel for vaccine reconstitution and administration. The hypo-
dermic needle also results in the creation of biohazardous sharps waste,
which pose the risk of infection to both patients and healthcare
workers. An estimated 33,800 HIV infections, 1.7 million hepatitis B
infections and 315,000 hepatitis C infections annually are caused from
unsafe injection practices (WHO | Injection safety policy and global
campaign,” 2016). Moreover, needle phobia often results in poor pa-
tient compliance (Taddio et al., 2012).
To retain their potency, many vaccines require cold chain storage,
from their distribution through to their administration. This has asso-
ciated cost challenges to low-resource countries and presents other
challenges in relation to geographical accessibility. The estimated cost
of cold chain storage is $200–$300million annually and cold chain
failures can result in vaccine shortages (Burstein et al., 2013). In ad-
dition, many vaccine formulations necessitate booster injections in
order to mount an appropriate immune response, which can be diﬃcult
to implement, subsequently resulting in poor vaccine coverage. The
World Health Organisation (WHO) estimates that the total number of
children who die annually from vaccine-preventable diseases is
1.5 million, accounting for 17% of all under 5 deaths (“Global
Immunization Data,” 2014). Thus, there is a pressing need to develop
safe, cost-eﬀective, innovative vaccine formulation strategies, to im-
prove coverage of currently available vaccines, while also developing
vaccines for infections for which no currently available vaccine exists,
to help control the incidence of infectious diseases.
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The skin represents an attractive route for vaccination, having the
advantage of increased patient compliance and increased vaccine ef-
fectiveness. The skin is densely populated with professional antigen
presenting cells (APCs). Dendritic cells (DCs) present in the dermis and
Langerhans cells (LCs) in the epidermis play a pivotal role in induction
of immune responses, whereby they capture foreign antigens and pre-
sent them in draining lymph nodes (Zaric et al., 2013a). The skin, by
virtue of its function in protection against water loss and environmental
inﬂuences, presents a major obstacle for intradermal (i.d) delivery
(Elias, 2008; Prausnitz et al., 2012). Human skin is composed of two
main compartments namely, the epidermis and the dermis. The skin’s
barrier function is almost entirely attributable to the outermost layer of
the epidermis, the stratum corneum (SC).
Dissolving microneedle patches (MNs) have been proposed as a
novel approach to increase skin permeability and may oﬀer an ideal
platform for i.d delivery (Ding et al., 2009; Rouphael et al., 2017). MNs
are minimally invasive devices that consist of a series of microscopic
projections attached to a base support (McCrudden et al., 2014a,b).
Upon application to the skin surface, MNs create microscopic holes in
the skin, bypassing the SC, and subsequently delivering their payload
into viable skin (Zaric et al., 2013b). MNs are typically fabricated such
that they are long enough to bypass the SC, yet are short enough to
avoid stimulation of dermal nerves. As such, they provide a painless,
minimally invasive method of delivery that is well accepted by human
subjects (Arya et al., 2017; Ripolin et al., 2017). MNs are advantageous
for vaccination; due to direct targeting of skin APC, they are dose
sparing, and oﬀer improved protection, while concurrently reducing
the requirement for usage by trained personnel (Quan et al., 2010;
Ripolin et al., 2017; Zaric et al., 2015). Further to this, MNs provide a
more simpliﬁed supply chain due to their ease of storage, distribution
and disposal due to avoidance generation of sharps wastes (Arya and
Prausnitz, 2016).
Dissolving MNs have received substantial interest for delivery of
currently licenced vaccines. For example, Matsuo et al. demonstrated
vaccine eﬃcacy against tetanus and diphtheria, malaria and inﬂuenza
using dissolving MNs (Matsuo et al., 2012). Moreover, a more recent
study by Rouphael and co-workers showed that dissolving MNs for
inﬂuenza vaccination was well tolerated and generated robust antibody
responses in humans (Rouphael et al., 2017). However, there has been
less research into the use of MNs for development of novel vaccines.
The objective of the present study was to design and evaluate a dis-
solving MN laden with heat-inactivated bacteria, as a novel, simpliﬁed
approach to vaccinating against a speciﬁc bacterium. Pseudomonas
aeruginosa strain PA01, was chosen as a model bacterium. Utilising a
simple, cost eﬀective fabrication process, P. aeruginosa was heat-in-
activated and formulated into dissolving MNs. As MNs oﬀer the possi-
bility for self-application, the expected beneﬁt of MN-mediated vacci-
nation with heat-inactivated bacteria would lie in the simplicity and
cost eﬀectiveness from the practical perspective. Whole heat-in-
activated vaccines are stable, safe for administration to im-
munocompromised patients and can be easily freeze dried and in-
corporated into MNs, thus allowing ease of transport and distribution,
and a cost-eﬀective approach to vaccinating against a speciﬁc pa-
thogen. This approach could potentially allow for mass immunisation
within developing countries, helping increase vaccine coverage. To the
best of our knowledge, this is the ﬁrst study that uses dissolving MN
arrays for delivery of a heat-inactivated bacterium, intended for vac-
cination against a bacteria for which no currently licenced vaccine
exists.
2. Materials and methods
2.1. Materials
Gantrez® S-97 (PMVE/MA), a copolymer of methyl-vinyl-ether and
maleic acid (MW 1,500,000 Da), was provided by Ashland (Tadworth,
Surrey, UK). Paraﬁlm M®, 127 µm thick, was obtained from BRAND
GMBH (Wertheim, Germany). Dulbecco’s phosphate buﬀered saline
(PBS) (endotoxin tested), Luria-Bertani broth and cetrimide agar were
obtained from Sigma-Aldrich (Dorset, UK). All other chemicals were of
analytical reagent grade. Rompun™ 100mg/ml, was purchased from
Bayer Healthcare LLC (Bergkamen Germany). Ketalar™ 10mg/ml ke-
tamine hydrochloric solution was purchased from Pﬁzer Ltd (Ramsgate
Road, Kent, UK).
2.2. Preparation of P. aeruginosa: culture, heat-inactivation and
lyophilisation
P. aeruginosa (strain PAO1), was grown on cetrimide agar at 37 °C
overnight. Post incubation a colony was selected and cultured overnight
in Luria-Bertani (LB) broth (5ml) at 37 °C in a rotatory incubator shaker
(180 rpm). Post incubation, the culture (5ml) was transferred into an
Erlenmeyer ﬂask containing a further 995ml of LB broth and incubated
as above. After incubation, the culture was transferred to 50ml Falcon
tubes and the bacteria was collected by centrifugation (4000 rpm for
20min), and the supernatant was subsequently removed. The resultant
P. aeruginosa pellets were washed twice by addition of phosphate buﬀer
(PB), followed by centrifugation as described above. Post washing, the
pellets were re-suspended in PB buﬀer and heat-killed by submersion in
a water-bath (65 °C) for 1 h. The suspension was inoculated onto LB
agar to ensure bacteria were not viable. The remaining suspension was
placed in a freezer (−80 °C) for 1 h. Once frozen, each Falcon tube lid
was replaced with a KimWipe (Kimberly-Clark Co., USA) and the tubes
were transferred to a side arm of a manifold-type freeze dryer (MiVac
freeze dryer) under a vacuum for 48 h before being removed and stored
until further use.
2.3. Formulation and fabrication of polymeric MN arrays
MNs were prepared from aqueous blends of Gantrez® S-97. A stock
of Gantrez® S-97 (40%) was diluted with the appropriate volume of a
suspension of P. aeruginosa diluted in phosphate buﬀered saline (PBS),
pH 7.4, to give a ﬁnal concentration of 20% Gantrez®S-97. One hundred
milligrams of this suspension, containing 200 µg of heat-inactivated P.
aeruginosa was poured onto silicon micromoulds. The micromoulds
contained 361 (19×19) pyramidal shaped needles, perpendicular to
the base, 500 µm in height, 300 µm wide and with 50 µm interspacing.
The arrays had areas of 0.6 cm2. A pressure of 3 bar was subsequently
used to force the MN formulation into the needles of the MNmould. The
MNs were dried under controlled temperature conditions (19 °C) for
24 h, before being carefully removed from the MN moulds and stored
until further use. A schematic representation showing the method of
production of dissolving MNs is shown in Fig. 1.
2.4. Scanning electron microscopy for imaging of MN arrays
When imaging MNs using scanning electron microscopy (SEM), MNs
were mounted onto an aluminium stub and observed under a TM3030
microscope (Hitachi Ltd, Japan). Micrographs of MN structures were
obtained and the surface morphology and height/width of individual
needles were examined/measured.
2.5. Mechanical characterisation of MNs
MNs were subjected to mechanical testing, as previously described
(McCrudden et al., 2014a,b). Mechanical testing of the MNs was per-
formed using a TA.XTPlus Texture Analyser (Stable MicroSystems,
Surrey, UK) in compression mode. MNs were attached to the cylindrical
probe of the TA. The probe was lowered vertically at a speed of ap-
proximately 1.19mm s−1 until the required force of 32 N/array was
applied. This has been shown to be the average maximum force a
human exerts when applying MNs (Larrañeta et al., 2014). Force was
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applied to the MNs for 30 s, the time recommended for MN application
(Donnelly et al., 2014), and the probe was subsequently retracted from
the testing area. MNs were visually examined pre- and post-application
of the compression load using a light microscope (GXMGE-5 digital
microscope, Laboratory Analysis Ltd, Devon, UK). The resulting images
were used to measure the heights of individual needles using ImageJ®
(National Institute of Health, Bethesda, USA) software. The percentage
change in MN height was subsequently calculated using Eq. (1) below,
where HBC is the needle heights before compression and HAC is the
needle heights after compression.
=
−
×%Compression HBC HAC
HBC
100 (1)
MN insertion testing was carried out as previously described by
Larreneta et al. whereby Paraﬁlm M® (PF), a blend of a hydrocarbon
wax and a polyoleﬁn, was used as a skin simulant (Larrañeta et al.,
2014). For this purpose, 8 PF layers were combined to form a PF ﬁlm of
approximately 1mm thickness. Prior to insertion, MNs were analysed
using a Leica EZ4 D digital microscope (Leica, Wetzler, Germany). The
Texture Analyser (TA) insertion was then performed in compression
mode. Brieﬂy, MNs were attached to the cylindrical probe of the TA and
a force was applied to the MNs. MN arrays were subsequently removed
from the PF sheet and each PF layer was unfolded. The holes created in
each layer were imaged using a Leica EZ4 D digital microscope (Leica,
Wetzler, Germany). For detection of the MN insertion holes, MNs were
placed between two polarized ﬁlters. The number of holes created in
each layer as a measure of insertion depth was subsequently calculated.
2.6. Analysis of MN dissolution using optical coherence tomography
The in vivo dissolution rate of MN inserted into murine ears was
conducted to determine the optimal MN application time for sub-
sequent in vivo studies. Brieﬂy, MN arrays were attached to translucent
double-sided tape and ﬁrmly attached to the dorsal surface of each
murine ear. MNs were inserted by application of thumb pressure to the
MN array (30 s). Inserted MNs were immediately viewed using an
EX1301 VivoSight® OCT Microscope with a hand-held probe, the con-
tacting surface of which had an area of 1 cm2. The swept-source Fourier
domain OCT system has a laser centre wave-length of 1305 ± 15 nm,
facilitating real-time high resolutions imaging of the upper skin layers
(< 7.5 µm lateral and<10 µm vertical resolution). The resulting 2D
images were analysed using ImageJ® (National Institute of Health,
Bethesda, USA) software. Obtained image ﬁles had a scale of
1.0 pixel= 4.2 µm, allowing accurate measurements of MN insertion
depth. Five replicates were performed per MN formulation and for each
MN inserted, 20 measurements of individual MN insertion depths were
taken by random selection of needles, from the 361 penetrating MNs in
each array. MN insertion data was presented as (± SD) of 20 replicate
measurements. The procedure was repeated at pre-determined time
points (5, 15, 30, 45, 60min).
2.7. MN-mediated vaccination studies
In vivo studies were performed on C57/BL6 mice, 6–8weeks old.
Mice were randomly divided into 2 groups, those that received blank
MNs (bMNs), or P. aeruginosa MNs (p.a MNs), n= 5/group. Brieﬂy,
mice were anaesthetised intraperitoneally (i.p) and immunised by
manual application of one MN to the dorsal surface of each ear for
5min, resulting in a corresponding dose of 400 µg of heat killed P.
aeruginosa. At 7 days post MN application, both vaccinated and un-
vaccinated mice were challenged with 2×106 colony forming units
(CFU) of P. aeruginosa (PA01), delivered intranasally (i.n). Each mouse
received a 20 µl volume of bacterial suspension, diluted in endotoxin-
free PBS and administered with a micropipette. Mice were carefully
monitored over the course of infection and weights were assessed.
Subsequently, 24 h post-challenge, mice were sacriﬁced and the lungs
and spleens were harvested for analysis of CFU counts.
2.7.1. Culture of P. aeruginosa for challenge study
P. aeruginosa was grown on cetrimide agar at 37 °C overnight.
Preparation of bacterial inoculum for challenge study was performed by
transferring a colony of P. aeruginosa into LB broth. The culture was
grown overnight at 37° C under gentle agitation. Following overnight
incubation, the bacteria were harvested by centrifuged for 25min at
22° C 4000 rpm and the supernatant was carefully removed. The pellet
was subsequently washed in PBS. Finally, optical density (OD) mea-
surements were used to dilute the bacterial suspension to the desired
concentration (106 CFU) using PBS and this was conﬁrmed by plating
serial dilutions of the preparations for enumeration of CFU post-over-
night incubation.
2.7.2. Analysis of colony forming units in the lungs and spleens 24 h post
bacterial inoculation
Lung and spleen tissue was homogenized under aseptic conditions
in 1ml of PBS in a sterile bijou using a mechanical homogeniser. Serial
dilutions of the homogenized organs (100 µl) were plated onto ce-
trimide agar (Sigma-Aldrich Dorset, UK) for analysis of bacterial load.
The agar plates were incubated overnight at 37 °C and the number of
CFUs counted for determination of bacterial load.
2.8. Statistical analysis
Data was compared using an unpaired, two-tailed student’s t-test. In
all cases, p < 0.05 was considered acceptable for rejection of the null
hypothesis. Statistical analysis was carried out using GraphPad Prism
version 5.0 (GraphPad Sotware Inc., San Diego, California).
3. Results
3.1. MN formulation and fabrication
Fig. 2 shows representative SEM images of dissolving MNs prepared
Fig. 1. A schematic representation of the steps involved in fabrication of dis-
solving MN laden with heat-inactivated Pseudomonas aeruginosa.
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from PMVE/MA and laden with heat-inactivated P. aeruginosa (p.a
MNs). The resulting MNs were approximately 500 µm in height, with a
width at base of approximately 300 µm, and the fabrication process
resulted in MNs with sharp needle tips, essential for insertion into
murine skin and successful vaccine delivery. A complete array of nee-
dles was formed and MN baseplates were of suﬃcient strength to be
easily removed from the moulds without damage being caused to the
array. The addition of P. aeruginosa did not appear to aﬀect MN struc-
ture, or the morphology of the individual needles.
3.2. Mechanical characterisation of MN arrays
Following application of the axial load, both MN types reduced in
height. The blank MNs (bMNs) reduced in height by 4.4% (Fig. 3C-i)
and the P. aeruginosa MNs (p.a MNs) by 4.7% (Fig. 3C-ii), respectively.
Thus, there were no signiﬁcant diﬀerences in the percentage reduction
in MN height between the two MN formulations (Fig. 3C-iii)
(p= 0.805), indicating that the loading of P. aeruginosa within the MNs
did not aﬀect their rigidity or compression characteristics. None of the
MNs, or the baseplates of the MNs fractured post-application of 32 N,
nor did the MNs appear to be compressed (Fig. 3D).
Post-application of an insertion force of 32 N, both MN types in-
serted into the PF layers (Fig. 3E) and the percentage of holes created in
each layer was subsequently analysed (Fig. 3F). Both MNs had similar
insertion proﬁles inserting into two PF layers (∼55% needles inserted),
with< 20% inserting into the third layer. As such, it can be estimated
that the MNs insertion depth was between 254 µm and 381 µm of the
total 500-µm needle height. These results are concurrent with pre-
viously reported studies with dissolving MN insertion into PF, whereby
the insertion was approximately 60% of the total needle height
(González-Vázquez et al., 2017; Larrañeta et al., 2014).
Notably, upon removal of MNs from the PF layers, all needles re-
mained attached to the baseplate and were not retained within the PF
layers. It was concluded that the p.a MNs produced, had suﬃcient
mechanical strength and insertion properties to successfully and con-
sistently penetrate the skin simulant PF and in a manner similar to that
of bMNs. From these results, it was deduced that the MNs produced
should be of suﬃcient strength to penetrate the SC in vivo. Furthermore,
the insertion and compression results obtained herein are comparable
to those of dissolving MNs previously used by our Group for successful
in vitro and in vivo delivery of various compounds, including antibiotics,
such as gentamicin, cardiovascular drugs, and various model protein
antigens (González-Vázquez et al., 2017; McCrudden et al., 2015;
Quinn et al., 2015; Zaric et al., 2013a).
3.3. Microneedle in-skin dissolution studies
Upon application, both MN formulations successfully traversed the
SC barrier and the needles penetrated into the skin layers, as high-
lighted in Fig. 4A. Furthermore, we evaluated the in situ dissolution rate
of both bMNs and p.a MNs in murine ears. Dissolution of the MNs began
immediately upon insertion into the skin and a gradual reduction in the
height of the MNs penetrating the skin layers was observed over time
(Fig. 4B). The p.a MNs had almost completely lost their needle proﬁle
and eﬃciently dissolved within the skin layers 5min post-insertion
(Fig. 4B). These results are in line with our previous study of dissolving
MNs dissolution in murine skin (Zaric et al., 2013b). In contrast, the
bMNs appeared to display slower dissolution kinetics and, after inser-
tion into the skin for 15min, the needles were still visible and retained
their needle proﬁle, thus suggesting that incorporation of the heat in-
activated P. aeruginosa positively aﬀected MN dissolution kinetics.
The OCT images showed no signiﬁcant diﬀerence between the in-
sertion proﬁle of the bMNs and the p.a MNs. These results are con-
current with the MN characterisation results, whereby no diﬀerence
between the mechanical characteristics, or insertion properties of the
two MN formulations was observed in PF layers (Fig. 3). Moreover,
examination of the height of MNs residing in skin 1 h post insertion was
carried out to conﬁrm the diﬀerences in dissolution kinetics between
the two MNs formulations. In parallel to the OCT images, showing in-
creased dissolution of the p.a MNs 1 h post insertion, the height of
bMNs residing in skin was approximately 150 µm, whereas the height of
the p.a MNs were all found to be<100 µm (Fig. 4D). Diﬀerences in MN
dissolution were also evidenced by the microscopic images of both MN
formulations 1 h post insertion in murine skin. Fig. 4C shows re-
presentative light microscope images of such MNs. These results imply
that incorporation of P. aeruginosa into the MNs resulted in an increased
MN dissolution rate compared to bMNs. Overall, the data presented
here conﬁrms that the polymeric MNs could successfully breach the SC
barrier of murine ears consistently, dissolve within the skin layers re-
leasing their payload and thus, could potentially be successfully used
for i.d delivery of heat-inactivated bacteria.
3.4. MN-mediated vaccination studies: Investigating the protective eﬃcacy
of MN-mediated delivery of heat-inactivated P. aeruginosa
The most appropriate site for application of dissolving MNs for
vaccine delivery was determined to be the dorsal surface of murine
ears, an attractive tissue target due to the enriched network of resident
APCs (Demuth et al., 2012; Zaric et al., 2013a). The MN application
time determined to be appropriate was 5min, as the greatest proportion
Fig. 2. Representative SEM images of MNs prepared from PMVE/MA laden with P. aeruginosa, showing: (A) fully formed individual needle, approximately 500 µm in
height and a width at base of 300 µm, (B) needle tip, (C) fully formed MN array and (D) row of individual needles. Scale bar as per images.
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of the length of each needle was dissolved within this time in the in vivo
dissolution studies (Fig. 4). The attachment of MNs onto surgical tape
and positioning of the MNs onto the dorsal surface of murine ears is
exempliﬁed in Fig. 5A. The attachment of MNs to surgical tape was
required to hold the MNs ﬁrmly in place (5min) for the vaccination
procedure and one MN was applied to the dorsal surface of either
mouse ear, before subsequently being removed and imaged to conﬁrm
dissolution and thus, successful delivery of heat inactivated P. aerugi-
nosa (Fig. 5B). The total P. aeruginosa content loaded in each entire
dissolving MN was approximately 200 µg. Therefore, as two dissolving
MNs were applied, each mouse had approximately 400 µg heat-in-
activated P. aeruginosa applied during the vaccination procedure.
Post-vaccination (7 days), mice underwent bacterial challenge by i.n
inoculation with a live culture of P. aeruginosa. Bacterial clearance has
been utilised as a measure of protection in vaccination trials and in in
vivo challenge models (Cripps et al., 1994) and as such, was used as a
measure of MN vaccination eﬀectiveness. The eﬃcacy of the polymeric
MNs laden with heat-inactivated P. aeruginosa to induce enhanced
bacterial clearance in the lungs of mice and to prohibit bacterial dis-
semination in the P. aeruginosa i.n challenge model was therefore
evaluated. Mice were challenged for 24 h, after which lungs and spleens
were harvested for analysis of bacterial enumeration. As evident in
Fig. 5D, MN-mediated vaccination of mice with p.a MNs resulted in MN
dissolution and in vivo delivery of P. aeruginosa in murine ears. This
resulted in a signiﬁcant reduction in the bacterial load in the lungs of
these mice 24 h post i.n challenge. Almost a two-log diﬀerence in lung
CFUs was evident in the mice that received the p.a MNs, compared to
their unvaccinated counterparts, those that received bMNs.
At 24 h post challenge, the number of CFUs in the spleens was
overall very low in both groups (Fig. 5D), since the mice were sacriﬁced
24 h post challenge, possibly leaving insuﬃcient time for bacterial
dissemination to this organ. It is however, noteworthy that there was a
marked reduction in the number of spleens infected with P. aeruginosa
within the vaccinated group (three out of ﬁve spleens were found to be
sterile), compared to the unvaccinated group, which received bMNs
(one out of ﬁve spleens was found to be sterile). These results collec-
tively demonstrate generation of a protective immune response in vivo
following application of our dissolving polymeric MNs, resulting in
enhanced bacterial clearance from the lungs and decreased likelihood
of systemic dissemination of P. aeruginosa.
Fig. 3. Mechanical characterisation of MN arrays.
Diagrammatic representation of the MN compression
(A) and insertion into Paraﬁlm M® (B) test method.
(C) MN height pre- and post-compression (32 N) at
1.19m/s, held for 30 s (mean ± SD, n= 5), bMNs
(i) and p.a MNs (ii). Comparison of percentage re-
duction in MN height of MN arrays prepared from
diﬀerent formulations (iii). (D) Representative
images of p.a MNs pre- (i) and (ii) post-application of
32 N (the scale bars represent 1mm). (E) Percentage
of holes created in each Paraﬁlm M® layer and their
corresponding insertion depth, using a force of 32 N
for bMNs and p.a MNs, mean ± SD, n=5. (F)
Representative microscope images of Paraﬁlm M®
layers after insertion of p.a MNs showing ﬁrst (1),
second (2), and third (3) Paraﬁlm M® layers (the
scale bar represents 2mm).
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4. Discussion
The emergence of multidrug-resistant bacteria for which no vac-
cines exist, has resulted in high mortality rates with limited or no
therapeutic interventions available (Jansen et al., 2018). Thus, there is
a necessity for greater consideration for the role of preventative vac-
cines to combat these pathogens. Moreover, there is a requirement for
alternative vaccine delivery mechanisms that circumvent the require-
ment for injection and cold chain storage. As such, utilising a simple,
cost eﬀective approach, P. aeruginosa (strain PA01) was used as a model
Fig. 4. MN arrays eﬃciently insert and dissolve in murine skin. MNs were applied to the dorsal surface of murine ears as depicted in the schematic image, and OCT
was subsequently used to image MNs inserted in the ears (A). Representative images of bMNs and p.a MNs inserted in skin showing MN dissolution as a function of
time, (T= time, 0, 5, 15, 30, 45 and 60min following skin insertion). (B), MNs were inserted in the skin for 1 h before being removed and imaged using a light
microscope, (i) bMNs (ii) p.a MNs. Representative images of entire MN arrays post application in murine skin are shown in (the scale bars represent 1 mm in bMN
image and 2mm in p.a MN image) (C). Graph (D) shows the height of MNs residing in skin 1 h post application. Results are presented as mean ± SD, n= 5MNs/
group. For each MN array at least 20 individual needles were measured.
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bacteria, heat-inactivated and formulated into dissolving MNs. This
study was conceived as a proof of concept study for investigating the
feasibility of taking a highly pathogenic bacterium, incorporating it into
dissolving MNs and successfully delivering the heat-inactivated bac-
terium in vivo, inducing protective immune responses with a view, in
time of working towards more relevant bacteria of the developing
world.
MNs were prepared using Gantrez®, previously shown to have been
successfully used in the formulation of dissolving MNs for delivery of
model protein antigens, importantly, without deterioration of the an-
tigens upon release from the MNs (Zaric et al., 2013a; McCrudden et al.,
2014a,b). MNs laden with a heat-inactivated bacterium and blank MNs
were prepared and characterized using tests deﬁned in previous works
(Lutton et al., 2015). In summary, MNs were found to be mechanically
sound and successfully inserted into the artiﬁcial membrane PF, re-
taining their needle structure upon removal. Moreover, OCT showed
that the MNs were of suﬃcient strength to penetrate murine skin and
the needles dissolved within the ﬁrst 5 min of skin application. From a
clinical viewpoint, rapid MN dissolution may be desirable for mon-
itoring of possible anaphylactic reactions.
Bacterial load post challenge is related to survival status and,
therefore, the enumeration of bacteria in vaccinated mice was in-
vestigated. MN i.d vaccination resulted in reduced bacterial load in the
lungs and reduced bacterial dissemination to the spleens. These results
are in line with those of Yang et al. who demonstrated reduced bacterial
loads, inﬂammatory cytokine expression (IL-6) and inﬂammatory cell
inﬁltration, following intramuscular (i.m) vaccination with POH and
adjuvant, in a challenge pneumonia model (Yang et al., 2017). Yanyan
and co-workers showed that vaccination with X-ray-irradiated
inactivated vaccine also controls CFUs in the lung and bacteria spread
to the main organs and blood of mice following challenge (Li et al.,
2016).
The use of lyophilised heat-inactivated vaccines delivered via dis-
solving MNs is advantageous for i.d vaccination. Firstly, heat-in-
activated vaccines are safe for administration to immunocompromised
patients (Ljungman, 2012). Administration of attenuated vaccines to
these patients could result in a heightened sensitivity response, and as
such, inactivated cells represent an attractive alternative (Walker,
2005). Also, the thermostability of inactivated vaccines within MNs
avoids the requirement of cold chain storage and its associated costs
(Mistilis et al., 2017; Zaric et al., 2013b). At present, inadequate fuel
and transport, necessary to ensure continuous running of cold chain
equipment, often leads to unreliable delivery of supplies and vaccine
stock-outs within developing countries (Shen et al., 2014). Moreover,
the use of MNs present several advantages over conventional needle
and syringe delivery system. One of the advantages is the prospect for
self-vaccination. This is an important advantage as eﬀective vaccines
are sometimes inaccessible in developing countries due to geographical
accessibility and lack of trained personnel for correct administration. It
is these countries that carry the greatest burden of infectious diseases
and struggle with vaccine compliance (Oliwa and Marais, 2017). The
Global Vaccine Action Plan (GVAP), approved by the WHO, identiﬁed
the requirement for improved delivery approaches for vaccination and
MNs may oﬀer a possible solution (WHO | Global Vaccine Action Plan
2011–2020, 2012). Additionally, dissolving MNs avoid the generation
of sharps waste (Arya and Prausnitz, 2016) and may overcome pro-
blems of needle phobia and subsequent vaccination non-compliance
(Taddio et al., 2012).
Fig. 5. MN-mediated vaccination studies. MNs were attached to surgical tape (the scale bar represents 500 μm) (A) and applied to murine ears for 5 min before being
removed and imaged via SEM to ensure complete dissolution (the scale bars represent 2 mm) (B). Post vaccination (day 7), mice were challenged for 24 h with a live
culture of P. aeruginosa (PA01), delivered intra-nasally (106 CFU, 20 µl) (C). The lungs and spleens were harvested for analysis of CFUs (D). Bar represents geometric
mean, n= 5 mice/group.
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The mechanism of vaccine delivery via dissolving MNs results in
polymer deposition in the skin. Although repeated application of dis-
solving MNs will not be required for vaccine delivery, regulatory bodies
will undoubtedly require assurance of polymer safety. Accordingly, an
understanding of the long-term eﬀects of polymer deposition will re-
quire further investigation to ensure they do not represent a danger.
While dissolving MNs are typically fabricated from biocompatible
polymers, they have not been used for i.d delivery. With the MNs uti-
lised in this particular study, each MN deposits approximately 5.4mg of
polymer per array, which is the polymer content in the needles only. As
highlighted such polymer deposition may result in eﬀects such as er-
ythema or hepatic/lymphatic accumulation and requires further in-
vestigation (Quinn et al., 2015). From a vaccination perspective, al-
though prime-boost applications may be required, MNs will not require
daily long-term application. Therefore, it is unlikely that such polymers
will have signiﬁcant long-term secondary/detrimental eﬀects.
As this was a proof of concept investigation, studies were not carried
out to elucidate the immunological mechanism by which p.a MNs
confer protective immunity. This research was designed to develop and
evaluate a pre-clinical MN delivery platform for i.d vaccination with
heat-inactivated bacteria. Consequently, we describe a simple, cost ef-
fective approach to vaccination that could be applicable to a range of
pathogens. Future studies are warranted to elucidate the mechanism of
immune responses elicited post MN-mediated vaccination against P.
aeruginosa. Such experiments should evaluate multiple cellular and
humoral facets of the immune response and the cross-protective eﬃ-
cacy among diﬀerent isolates of P. aeruginosa. Moreover, studies should
also take into account the eﬀects of polymer deposition and subsequent
impact on immune response. In addition, prime-boost regimes and an
investigation into long-term protection are warranted.
5. Conclusions
The work presented here reports successful formulation and char-
acterisation of dissolving MNs laden with heat-inactivated P. aeruginosa
for i.d vaccination. Notably, MNs were fabricated using pressure only,
highlighting the simplicity and cost-eﬀectiveness in the strategy em-
ployed. In addition, in vivo murine challenge studies conﬁrmed delivery
and the generation of an immune response, resulting in reduced bac-
terial load in the lungs and spleens of vaccinated mice. Together, these
results suggest that dissolving MN-mediated i.d vaccination is a po-
tentially viable delivery system. This technology could simplify vaccine
administration and distribution in developing countries, thus improving
vaccine coverage. Heat-inactivation of bacteria and its incorporation
into MNs oﬀers a novel, simpliﬁed approach to vaccination against a
speciﬁc pathogen. This is the ﬁrst reported study utilising a dissolving
MN platform for successful delivery of a lyophilised heat-inactivated
bacterium for vaccination against a pathogen for which no currently
licensed vaccine exists.
This was an initial, but important study highlighting the potential of
MNs for delivery of heat-inactivated vaccines. We anticipate that this
dissolving MN system, due to its simplicity and ease of use, could po-
tentially have a substantial impact on the prevention of infectious dis-
ease. Dissolving MNs oﬀer the prospect of mass vaccination and the
incorporation of heat-inactivated bacteria provides a simpliﬁed ap-
proach, which could easily be implemented in countries of the devel-
oping world. This was a proof of concept study and prior to this tech-
nology being applied to patients; several additional studies are
warranted, including studies to elucidate the mechanisms of induced
immune protection and patient usability/acceptability proﬁles. This
technology clearly holds much potential and warrants further in-
vestigation.
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